During last week’s Q3 earnings call, a Wall Street analyst asked Chromadex CEO Rob Fried to compare the bodily impact of the new Niagen+ IV to NAD+ boosting supplement Niagen (Nicotinamide Riboside “NR” (FAQs) (Anecdotes)). Here’s the question followed by CEO Fried’s response:
